NOx in exhaled breath condensate is related to allergic sensitization in young and middle-aged adults

Fahad M Aldakheel, Jane E. Bourke, Paul S. Thomas, Melanie C Matheson, Michael J. Abramson, Garun S. Hamilton, Caroline J Lodge, Bruce R. Thompson, E. Haydn Walters, Katrina J. Allen, Bircan Erbas, Jennifer L. Perret, Shyamali C. Dharmage, Adrian J Lowe

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Asthma and allergic diseases are heterogeneous. Measurement of biomarkers in exhaled breath condensate (EBC) may help to discriminate between different phenotypes and may assist with clinical prognostication. Objectives: We aimed to assess associations between total nitric oxide products (NOx) in EBC and different allergic phenotypes and lung function in young and middle-aged adults. Methods: Cross-sectional analyses were nested within two Australian longitudinal studies, the Melbourne Atopy Cohort Study (MACS, mean age 17.8 years) and the Tasmanian Longitudinal Health Study (TAHS, mean age 49.4 years). Levels of EBC NOx were determined by Griess-reaction fluorescent method. Associations were assessed between EBC NOx and different allergic phenotypes, lung function and airway reactivity. Results: Atopy, with or without asthma or rhinitis, was associated with increased EBC NOx levels particularly in individuals with poly-aero-sensitization. These findings were generally consistent across the two age groups. In the older cohort, use of ICS in the previous 12 months masked the association between sensitization and EBC NOx (OR = 0.64, 95% CI = 0.21-1.96, p for interaction = 0.05). Conclusions and clinical relevance: In these population-based samples, EBC NOx was most strongly associated with atopic sensitization, rather than either current asthma or rhinitis, possibly indicating underlying increased airway inflammation associated with atopy. Therefore, EBC NOx could be a key predictor of atopy in both young and middle-aged adults, regardless of the presence of concomitant asthma or rhinitis.

Original languageEnglish
Pages (from-to)171-179
Number of pages9
JournalClinical and Experimental Allergy
Volume49
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • asthma
  • atopy
  • exhaled breath condensate
  • rhinitis
  • total nitric oxide

Cite this

Aldakheel, Fahad M ; Bourke, Jane E. ; Thomas, Paul S. ; Matheson, Melanie C ; Abramson, Michael J. ; Hamilton, Garun S. ; Lodge, Caroline J ; Thompson, Bruce R. ; Haydn Walters, E. ; Allen, Katrina J. ; Erbas, Bircan ; Perret, Jennifer L. ; Dharmage, Shyamali C. ; Lowe, Adrian J. / NOx in exhaled breath condensate is related to allergic sensitization in young and middle-aged adults. In: Clinical and Experimental Allergy. 2019 ; Vol. 49, No. 2. pp. 171-179.
@article{43b17748a30148e98a25a6d24946e49a,
title = "NOx in exhaled breath condensate is related to allergic sensitization in young and middle-aged adults",
abstract = "Background: Asthma and allergic diseases are heterogeneous. Measurement of biomarkers in exhaled breath condensate (EBC) may help to discriminate between different phenotypes and may assist with clinical prognostication. Objectives: We aimed to assess associations between total nitric oxide products (NOx) in EBC and different allergic phenotypes and lung function in young and middle-aged adults. Methods: Cross-sectional analyses were nested within two Australian longitudinal studies, the Melbourne Atopy Cohort Study (MACS, mean age 17.8 years) and the Tasmanian Longitudinal Health Study (TAHS, mean age 49.4 years). Levels of EBC NOx were determined by Griess-reaction fluorescent method. Associations were assessed between EBC NOx and different allergic phenotypes, lung function and airway reactivity. Results: Atopy, with or without asthma or rhinitis, was associated with increased EBC NOx levels particularly in individuals with poly-aero-sensitization. These findings were generally consistent across the two age groups. In the older cohort, use of ICS in the previous 12 months masked the association between sensitization and EBC NOx (OR = 0.64, 95{\%} CI = 0.21-1.96, p for interaction = 0.05). Conclusions and clinical relevance: In these population-based samples, EBC NOx was most strongly associated with atopic sensitization, rather than either current asthma or rhinitis, possibly indicating underlying increased airway inflammation associated with atopy. Therefore, EBC NOx could be a key predictor of atopy in both young and middle-aged adults, regardless of the presence of concomitant asthma or rhinitis.",
keywords = "asthma, atopy, exhaled breath condensate, rhinitis, total nitric oxide",
author = "Aldakheel, {Fahad M} and Bourke, {Jane E.} and Thomas, {Paul S.} and Matheson, {Melanie C} and Abramson, {Michael J.} and Hamilton, {Garun S.} and Lodge, {Caroline J} and Thompson, {Bruce R.} and {Haydn Walters}, E. and Allen, {Katrina J.} and Bircan Erbas and Perret, {Jennifer L.} and Dharmage, {Shyamali C.} and Lowe, {Adrian J}",
year = "2019",
month = "2",
doi = "10.1111/cea.13251",
language = "English",
volume = "49",
pages = "171--179",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "2",

}

Aldakheel, FM, Bourke, JE, Thomas, PS, Matheson, MC, Abramson, MJ, Hamilton, GS, Lodge, CJ, Thompson, BR, Haydn Walters, E, Allen, KJ, Erbas, B, Perret, JL, Dharmage, SC & Lowe, AJ 2019, 'NOx in exhaled breath condensate is related to allergic sensitization in young and middle-aged adults', Clinical and Experimental Allergy, vol. 49, no. 2, pp. 171-179. https://doi.org/10.1111/cea.13251

NOx in exhaled breath condensate is related to allergic sensitization in young and middle-aged adults. / Aldakheel, Fahad M; Bourke, Jane E.; Thomas, Paul S.; Matheson, Melanie C; Abramson, Michael J.; Hamilton, Garun S.; Lodge, Caroline J; Thompson, Bruce R.; Haydn Walters, E.; Allen, Katrina J.; Erbas, Bircan; Perret, Jennifer L.; Dharmage, Shyamali C.; Lowe, Adrian J.

In: Clinical and Experimental Allergy, Vol. 49, No. 2, 02.2019, p. 171-179.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - NOx in exhaled breath condensate is related to allergic sensitization in young and middle-aged adults

AU - Aldakheel, Fahad M

AU - Bourke, Jane E.

AU - Thomas, Paul S.

AU - Matheson, Melanie C

AU - Abramson, Michael J.

AU - Hamilton, Garun S.

AU - Lodge, Caroline J

AU - Thompson, Bruce R.

AU - Haydn Walters, E.

AU - Allen, Katrina J.

AU - Erbas, Bircan

AU - Perret, Jennifer L.

AU - Dharmage, Shyamali C.

AU - Lowe, Adrian J

PY - 2019/2

Y1 - 2019/2

N2 - Background: Asthma and allergic diseases are heterogeneous. Measurement of biomarkers in exhaled breath condensate (EBC) may help to discriminate between different phenotypes and may assist with clinical prognostication. Objectives: We aimed to assess associations between total nitric oxide products (NOx) in EBC and different allergic phenotypes and lung function in young and middle-aged adults. Methods: Cross-sectional analyses were nested within two Australian longitudinal studies, the Melbourne Atopy Cohort Study (MACS, mean age 17.8 years) and the Tasmanian Longitudinal Health Study (TAHS, mean age 49.4 years). Levels of EBC NOx were determined by Griess-reaction fluorescent method. Associations were assessed between EBC NOx and different allergic phenotypes, lung function and airway reactivity. Results: Atopy, with or without asthma or rhinitis, was associated with increased EBC NOx levels particularly in individuals with poly-aero-sensitization. These findings were generally consistent across the two age groups. In the older cohort, use of ICS in the previous 12 months masked the association between sensitization and EBC NOx (OR = 0.64, 95% CI = 0.21-1.96, p for interaction = 0.05). Conclusions and clinical relevance: In these population-based samples, EBC NOx was most strongly associated with atopic sensitization, rather than either current asthma or rhinitis, possibly indicating underlying increased airway inflammation associated with atopy. Therefore, EBC NOx could be a key predictor of atopy in both young and middle-aged adults, regardless of the presence of concomitant asthma or rhinitis.

AB - Background: Asthma and allergic diseases are heterogeneous. Measurement of biomarkers in exhaled breath condensate (EBC) may help to discriminate between different phenotypes and may assist with clinical prognostication. Objectives: We aimed to assess associations between total nitric oxide products (NOx) in EBC and different allergic phenotypes and lung function in young and middle-aged adults. Methods: Cross-sectional analyses were nested within two Australian longitudinal studies, the Melbourne Atopy Cohort Study (MACS, mean age 17.8 years) and the Tasmanian Longitudinal Health Study (TAHS, mean age 49.4 years). Levels of EBC NOx were determined by Griess-reaction fluorescent method. Associations were assessed between EBC NOx and different allergic phenotypes, lung function and airway reactivity. Results: Atopy, with or without asthma or rhinitis, was associated with increased EBC NOx levels particularly in individuals with poly-aero-sensitization. These findings were generally consistent across the two age groups. In the older cohort, use of ICS in the previous 12 months masked the association between sensitization and EBC NOx (OR = 0.64, 95% CI = 0.21-1.96, p for interaction = 0.05). Conclusions and clinical relevance: In these population-based samples, EBC NOx was most strongly associated with atopic sensitization, rather than either current asthma or rhinitis, possibly indicating underlying increased airway inflammation associated with atopy. Therefore, EBC NOx could be a key predictor of atopy in both young and middle-aged adults, regardless of the presence of concomitant asthma or rhinitis.

KW - asthma

KW - atopy

KW - exhaled breath condensate

KW - rhinitis

KW - total nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=85052937626&partnerID=8YFLogxK

U2 - 10.1111/cea.13251

DO - 10.1111/cea.13251

M3 - Article

VL - 49

SP - 171

EP - 179

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 2

ER -